MedPage TodayEpilepsy Has Immune Origin in Some PatientsMedPage TodayEleven of the IgG-positive patients were offered immunotherapies based on intravenous methylprednisolone plus other treatments — donor immunoglobulins, rituximab (Rituxan), or plasma…
|
Biogen Idec presentará nuevos datos ampliados de su sólida cartera de …
Lainformacion.com PROCESO DE ALTO RENDIMIENTO DE DACLIZUMAB (DAC HYP): está siendo desarrollado como una inyección para administrar una vez al mes. Se considera que DAC HYP se dirige a las células inmunológicas activadas que pueden desempeñar un … |
Biogen Idec to present new drug data at ECTRIMS 2013Zenopa… including information on both approved and investigational products. The firm will share the latest clinical findings on established therapies such as Tysabri, Tecfidera and Fampyra, as well…
|
Difficulties in extending patent protection for uses of known drugs in Europe …
Lexology (registration) A case in point is the recent EPO Board of Appeals decision in T0734/12 in relation to a patent (EP1613350) in which Genentech claimed use of rituximab (Rituxan®) to treat patients who were suffering from rheumatoid arthritis (RA) who were refractory … |
Teleborsa |
Biogen Idec presenterà all’ECTRIMS numerosi nuovi dati relativi alla suo ampia …
Teleborsa PROCESSO DACLIZUMAB AD ELEVATO RENDIMENTO (DAC HYP): in fase di sviluppo come iniezione sottocutanea da somministrare mensilmente. Si ritiene che DAC HYP abbia come target le cellule immunitarie attive che possono giocare un ruolo … |
|
Enbrel, Humira “still mainstay” first-line US RA biologics
PharmaTimes In addition, treating physicians told the study that they would consider switching 22%-34% of their patients who are currently being treated with Orencia IV, and 20%-25% of their patients who are receiving Genentech/Biogen Idec’s Rituxan (rituximab) or … |
|
Biogen Idec présentera de nouvelles données approfondies de son portefeuille …
BFMTV.COM PROCESSUS À HAUT RENDEMENT DU DACLIZUMAB (DAC HYP – DACLIZUMAB HIGH-YIELD PROCESS) : une thérapie d’injection sous-cutanée mensuelle en cours d’élaboration. Le DAC HYP semble cibler les cellules immunitaires activées qui peuvent … |
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis …Financial PostDACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune cells…
|
Biogen Idec stellt umfangreiche neue Daten zu seinem robusten Portfolio für …
Finanzen.net DACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): Dieser Wirkstoff wird als einmal monatlich verabreichte subkutane Injektion entwickelt. Es wird angenommen, dass DAC HYP auf die aktivierten Immunzellen abzielt, die eine sehr wichtige Rolle bei MS … |
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis …Wall Street JournalDACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune …